Long-Term Treatment of Chronic Myelogenous Leukemia with Different Interferons: Results from Three Studies

References

• Fialkow P. J., Jacobson R. J., Papayannopoulu T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet, and monocyte/macrophage. Am. J. Med. 1977; 63: 125–130
   PubMed Web of Science ®Google Scholar
• Rosenthal S., Canellos G. P., DeVita V. T., Gralnick H. R. Characteristics of blast crisis in chronic granulocytic leukemia. Blood 1977; 49: 705–709
   PubMed Web of Science ®Google Scholar
• Canellos G. P. Chronic granulocytic leukemia. Med. Clin. N. Amer. 1976; 60: 1001–1018
   PubMed Web of Science ®Google Scholar
• Nowell P. C., Hungerford D. A. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497
   Web of Science ®Google Scholar
• Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290
   PubMed Web of Science ®Google Scholar
• De Klein A., van Kessel A. G., Grosveld G., Bartram C. R., Hagemeijer A., Bootsma D., Spurr N. K., Heisterkamp N., Groffen J., Stephenson J. R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelogenous leukemia. Nature 1982; 300: 765–767
   PubMed Web of Science ®Google Scholar
• Stam K., Heisterkamp N., Grosveld G., de Klein A., Verma R. S., Coleman M., Dosik H., Groffen J. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N. Engl. J. Med. 1985; 313: 1429–1433
   PubMed Web of Science ®Google Scholar
• Ben-Nariah Y., Daley G. Q., Mes-Masson A. M., Witte O. N., Baltimore D. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212–214
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Van Etten R. A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Shtarid M., Talpaz M., Blick M., Romero P., Kantarjian H., Taylor K., Trujillo J., Schachner J., Gutterman J. U., Kurzrock R. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J. Clin. Oncol. 1988; 6: 1569–1575
   PubMed Web of Science ®Google Scholar
• Groffen J., Stephenson J. R., Heisterkamp N., de Klein A., Bartram C. R., Grosveld G. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93–98
   PubMed Web of Science ®Google Scholar
• Mills K. I., Stewart J., Burnett A. K. Correlation of M-bcr breakpoint with different chromosomal abnormalities in blast crisis Ph1-positive CML. Leukemia Res. 1991; 15: 999–1003
   PubMed Web of Science ®Google Scholar
• Benn P., Soper L., Eisenberg A., Silver R. T., Coleman M., Cacciapaglia B., Bennet L., Baird M., Silverstein M., Berger C., Bernhardt B. Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer Genet. Cytogenet. 1987; 29: 1–7
   PubMed Web of Science ®Google Scholar
• Lange W., Snyder D. S., Castro R., Rossi J. J., Blume K. G. Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. Blood 1989; 73: 1735–1741
   PubMed Web of Science ®Google Scholar
• Delfau M.-H., Kerckaert J.-P., d'Hooghe M. C., Fenaux P., Lai J. L., Jouet J.-P., Grandchamp B. Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. Leukemia 1990; 4: 1–5
   PubMed Web of Science ®Google Scholar
• Martiat P., Maisin D., Philippe M., Ferrant A., Michaux J. L., Cassiman J. J., Van den Berghe H. Detection of residual bcr/abl transcripts in chronic myeloid leukemia patients in complete remission using the polymerase chain reaction and nested primers. Brit. J. Haematol. 1990; 75: 355–358
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Clift R. A., Fefer A., Appelbaum F. R., Beatty P., Bensinger W. I., Buckner C. D., Cheever M. A., Deeg H. J., Doney K., Flournoy N., Greenberg P., Hansen J. A., Martin P., McGuffin R., Ramberg R., Sanders J. E., Singer J., Stewart P., Storb R., Sullivan K., Weiden P. L., Witherspoon R. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann. Intern. Med. 1986; 104: 155–163
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Clift R. A. Indications for marrow transplantation in chronic myelogenous leukemia. Blood 1989; 73: 861–864
   PubMed Web of Science ®Google Scholar
• Schaefer U. W., Beelen D., Graeven U., Kloke O., Niederle N., Quabeck K., Sayer H., Schmidt C. G. Chronic myelocytic leukemia and interferon, D. Huhn, K. P. Hellriegel, N. Niederle. Springer Verlag, Heidelberg: 1988; 139–142, Allogeneic bone marrow transplantation in chronic myelogenous leukemia. In:
   Google Scholar
• Oldstein D., Laszlo L. Interferon therapy in cancer: from imaginon to interferon. Cancer Res. 1986; 46: 4315–4329
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K. B., Keating M. J., Trujillo J., Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280–1288
   PubMed Web of Science ®Google Scholar
• Alimena G., Morra E., Lazzarino M., Liberati A. M., Montefusco E., Inverardi D., Bernasconi P., Mancini M., Donti E., Grigniani F., Bernasconi C., Dianzani F., Mandelli F. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–647
   PubMed Web of Science ®Google Scholar
• Niederle N., Kloke O., Osieka R., Wandl U., Opalka B., Schmidt C. G. Interferon alpha-2b in the treatment of chronic myelogenous leukemia. Sem. Oncol. 1987; 14: 629–35
   Web of Science ®Google Scholar
• Kloke O., Becher R., Niederle N. Response to combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukemia. Blut 1987; 55: 453–458
   PubMedGoogle Scholar
• Kurzrock R., Talpaz M., Kantarjian H., Walters R., Saks S., Trujillo J. M., Gutterman J. U. Therapy of chronic myelogenous leukemia with recombinant interferon gamma. Blood 1987; 70: 943–947
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., McCredie K., Trujillo J. M., Keating M. J., Gutterman J. U. Hematologic remission and cytogenetic improvement induced by re-combinant human interferon alpha in chronic myelogenous leukemia. N. Engl. J. Med. 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J., Gutterman J. U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Intern. Med. 1991; 14: 532–538
   Web of Science ®Google Scholar
• Yoffe G., Blick M., Kantarjian H., Spitzer G., Gutterman J., Talpaz M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 1987; 69: 961–963
   PubMed Web of Science ®Google Scholar
• Niederle N., Moritz T., Kloke O., Wandl U., May D., Becher R., Franz T., Opalka B., Schmidt C. G. Interfron alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: Initial response and long term results in 54 patients. Eur. J. Cancer 1991; 27: S7–S14
   PubMed Web of Science ®Google Scholar
• Kloke O., Wandl U., Opalka B., Moritz T., Nagel-Hiemke M., Franz T., Becher R., Hirche H., Seeber S., Niederle N. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low dose IFN-gamma in chronic myelogenous leukaemia. Eur. J. Haematol. 1992; 48: 93–98
   PubMed Web of Science ®Google Scholar
• Wandl U. B., Kloke O., Nagel-Hiemke M., Moritz T., Becher R., Opalka B., Holtkamp W., Bartels H., Seeber S., Niederle N. Interferon alpha-2b plus interferon gamma in pretreated CML patients. Brit. J. Haematol. 1992; 81: 516–519
   PubMed Web of Science ®Google Scholar
• Talpaz M., McCredie K. B., Mavligit G. M., Gutterman J. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689–692
   PubMed Web of Science ®Google Scholar
• Niederle N., Kloke O. Interferon in the treatment of hairy cell leukemia and chronic myelogenous leukemia. In:. Interferons in oncology. Current status and future directions, J. F. Smythe. European School of Oncology Monographs, Springer Verlag, Berlin, Heidelberg, New York, London, ParisTokio 1987; 11–24
   Google Scholar
• de Klein A., van Agthoven T., Groffen C., Heisterkamp N., Groffen J., Grosveld G. Molecular analysis of both translocation products of a Philadelphia-positive CML patient. Nucleic Acids Res. 1986; 14: 7074–7082
   Web of Science ®Google Scholar
• Opalka B., Wandl U., Kloke O., Oberle C., Koppe J., Niederle N., Schmidt C. G. A Pvull polymorphism of the bcr region in patients with hematopoietic disorders and their families. Blood 1989; 73: 814–817
   PubMed Web of Science ®Google Scholar
• Opalka B., Wandl U. B., Becher R., Kloke O., Nagel-Hiemke M., Moritz T., Beer U., Seeber S., Niederle N. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon α-2b alone or in combination with interferon α. Blood 1991; 78: 2188–2193
   PubMed Web of Science ®Google Scholar
• Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156–159
   PubMed Web of Science ®Google Scholar
• Roth M. S., Antin J. H., Ginsburg D. Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood 1989; 74: 882–885
   PubMed Web of Science ®Google Scholar
• Freund M., von Wussow P., Diedrich H., Eisert R., Link H., Wilke H., Buchholz F., LeBlanc S., Fonatsch C., Deicher H., Poliwoda H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Brit. J. Haematol. 1989; 72: 350–356
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Smith T. L., Talpaz M., McCredie K. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am. J. Med. 1990; 88: 1–8
   PubMed Web of Science ®Google Scholar
• Opalka B., Kloke O., Wandl U., Becher R., Niederle N. Treatment of chronic myelogenous leukaemia with interferons: haematologic, cellular and genetic investigations. In:. Modern Trends in Human Leukaemia VIII, R. Neth, R. Gallo, M. F. Greaves, G. Gaedicke, S. Gohla, K. Mannweiler, J. Ritter. Springer Verlag, Tokio 1990; 134–138, Berlin, Heidelberg, New York, London, Paris
   Google Scholar
• Opalka B., Kloke O., Bartram C. R., Beer U., Janssen J. W. G., Niederle N., Wandl U. Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia. Lancet 1989; 1: 1334
   PubMed Web of Science ®Google Scholar
• Pignon J. M., Henni T., Anselem S., Vidaud M., Duquesnoy P., Vernant J. P., Kuentz M., Cordonnier C., Rochant H., Goossens M. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia 1990; 4: 83–86
   PubMed Web of Science ®Google Scholar
• Kloke O., Niederle N. Development and mechanisms of interferon resistance. Cancer Treatm. Rev. 1990; 17: 81–88
   PubMed Web of Science ®Google Scholar
• Kessler D. S., Pine R., Pfeffer L. M., Levy D., Darnell J. E., Jr. Cells resistant to interferon are defective in activation of a promoter-binding factor. Europ. Mol. Biol. Org. J. 1988; 7: 3779–3783
   PubMed Web of Science ®Google Scholar
• Clauss I. M., Vandenplas B., Wathelet M. G., Dorval C., Delforge A., Content J., Stryckmans P., Huez G. A. Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-α treatment. Blood 1990; 76: 2337–2342
   PubMed Web of Science ®Google Scholar
• Howard O. M. Z., Talpaz M., Kantarjian H., Seong D., Wedrychowski A., Paslidis N., Hester J., Cork A., Turpin J., Lopez-Berstein G., Trujillo J. J., Gutterman J., Freireich E., Deisseroth A. Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Blood 1990; 76: 1117–1130
   PubMed Web of Science ®Google Scholar